These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17662321)

  • 21. Level of understanding of co-trimoxazole use among HIV infected, recurrent pulmonary tuberculosis suspects at a national referral tuberculosis clinic in Kampala, Uganda: a qualitative analysis.
    Okwera A; Mafigiri DK; Guwatudde D; Whalen C; Joloba M
    Afr Health Sci; 2015 Mar; 15(1):49-57. PubMed ID: 25834530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV: opportunistic infections.
    Ioannidis J; Wilkinson D
    Clin Evid; 2003 Jun; (9):795-816. PubMed ID: 15366175
    [No Abstract]   [Full Text] [Related]  

  • 23. Co-trimoxazole in HIV-1 infection.
    Badri M; Maartens G; Wood R; Ehrlich R
    Lancet; 1999 Jul; 354(9175):334-5. PubMed ID: 10440331
    [No Abstract]   [Full Text] [Related]  

  • 24. Reconsidering empirical cotrimoxazole prophylaxis for infants exposed to HIV infection.
    Gill CJ; Sabin LL; Tham J; Hamer DH
    Bull World Health Organ; 2004 Apr; 82(4):290-7. PubMed ID: 15259258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Developing an evidence-based, preventive care package for persons with HIV in Africa.
    Mermin J; Bunnell R; Lule J; Opio A; Gibbons A; Dybul M; Kaplan J
    Trop Med Int Health; 2005 Oct; 10(10):961-70. PubMed ID: 16185230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomised, placebo-controlled trial to evaluate co-trimoxazole to reduce mortality and morbidity in HIV-infected post-natal women in Zambia (TOPAZ).
    Nunn AJ; Mwaba PB; Chintu C; Crook AM; Darbyshire JH; Ahmed Y; Zumla AI
    Trop Med Int Health; 2011 Apr; 16(4):518-26. PubMed ID: 21281407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Acute respiratory failure responsive to cotrimoxazole and corticosteroïds in an AIDS patient].
    Thomas F; Laidi F; Boughrara E; Clavier H; Kalfon P
    Rev Pneumol Clin; 2001 Feb; 57(1 Pt 1):32-4. PubMed ID: 11373602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can OI prophylaxis be stopped in patients responding to HAART?
    Boyle BA
    AIDS Read; 1999 Jul; 9(4):240-2, 245. PubMed ID: 12737113
    [No Abstract]   [Full Text] [Related]  

  • 29. Utilization of a basic care and prevention package by HIV-infected persons in Uganda.
    Colindres P; Mermin J; Ezati E; Kambabazi S; Buyungo P; Sekabembe L; Baryarama F; Kitabire F; Mukasa S; Kizito F; Fitzgerald C; Quick R
    AIDS Care; 2008 Feb; 20(2):139-45. PubMed ID: 17896196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa.
    Harries AD; Zachariah R; Lawn SD
    Int J Tuberc Lung Dis; 2009 Jan; 13(1):6-16. PubMed ID: 19105873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis-HIV-co-infected patients in resource-constrained settings.
    Gray A; Abdool Karim SS; Gengiah TN
    AIDS; 2006 Jan; 20(2):302-3. PubMed ID: 16511431
    [No Abstract]   [Full Text] [Related]  

  • 32. Role of trimethoprim-sulphamethoxazole in preventing HIV-associated bacteraemia.
    Tumbarello M; Tacconelli E; Cauda R; Ortona L
    AIDS; 1997 Jul; 11(8):1070-1. PubMed ID: 9223752
    [No Abstract]   [Full Text] [Related]  

  • 33. Children dying from pneumonia: are we doing enough?
    Gie RP; Enarson PM
    Int J Tuberc Lung Dis; 2006 Aug; 10(8):828. PubMed ID: 16898364
    [No Abstract]   [Full Text] [Related]  

  • 34. Linear IgA bullous dermatosis of childhood: treatment with dapsone and co-trimoxazole.
    Pulimood S; Ajithkumar K; Jacob M; George S; Chandi SM
    Clin Exp Dermatol; 1997 Mar; 22(2):90-1. PubMed ID: 9330073
    [No Abstract]   [Full Text] [Related]  

  • 35. Continuation with cotrimoxazole prophylaxis for the prevention of opportunistic infections in HIV-infected persons in rural Zimbabwe: feasibility, obstacles and opportunities.
    Alkatout I; Vineberg R; Schulz U; Anlauf M; Thistle P
    AIDS Care; 2007 Apr; 19(4):478-81. PubMed ID: 17453586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Assessment of compliance with ARV treatment in Africa].
    Mouala C; Roux P; Okome M; Sentenac S; Okome F; Nziengui U; Olivier F; Benjaber K; Rey JL
    Med Trop (Mars); 2006 Dec; 66(6):610-4. PubMed ID: 17286034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The estimated burden of HIV/AIDS in Uganda, 2005-2010.
    Hladik W; Musinguzi J; Kirungi W; Opio A; Stover J; Kaharuza F; Bunnell R; Kafuko J; Mermin J
    AIDS; 2008 Feb; 22(4):503-10. PubMed ID: 18301063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Visceral leishmaniasis and HIV infection in the HAART era].
    Marques N; Cabral S; Sá R; Coelho F; Oliveira J; Saraiva da Cunha JG; Meliço Silvestre A
    Acta Med Port; 2007; 20(4):291-8. PubMed ID: 18198072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The expanding role of co-trimoxazole in developing countries.
    Church JA; Fitzgerald F; Walker AS; Gibb DM; Prendergast AJ
    Lancet Infect Dis; 2015 Mar; 15(3):327-39. PubMed ID: 25618179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New perspectives in the chemotherapy of toxoplasmosis.
    Terragna A; Canessa A
    J Chemother; 1989 Jul; 1(4 Suppl):935-7. PubMed ID: 16312712
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.